In order to secure access to important antibiotics, the government has decided to investigate whether a model with state premiums may be worth testing. The proposal will be presented today, Tuesday, at the “Almedalen political week” in Visby.
While the use of antibiotics must be reduced in order to slow the development of AMR, health care must also have access to effective antibiotics and new antibiotic agents must be developed. But to invest in R&D for new medicines that preferably should not be used is not interesting for pharmaceutical companies.
- Antibiotics that are used only in rare cases will be very expensive and not profitable to use in Sweden with our situation as regards AMR. We need to find a new economic model to ensure the availability, says minister for health, Mr. Gabriel Wikström.
The government has now given the Public Health Agency the task to examine whether a system including state premiums to pharmaceutical companies would be worth trying. The premium would guarantee an income to the companies and thus helping to secure that pharmaceutical companies will develop new antibiotic agents.
- If we find a good model, it can also entice companies to invest in new antibiotics. For antibiotics the usual economic models for medicine, where large initial costs of research are paid through high prices at the beginning of the product cycle, do not apply. That model does not work for antibiotics that are only kept as a reserve and should preferably not be used at all, says Gabriel Wikström.
The model of a premium system is based on a proposal by the trade association LIF.
- What's really exciting is that we can be the first to solve this problem. If it works, we believe that it will inspire other countries, says Karolina Antonov, head of analysis at LIF.
The article was originally published here (in Swedish).